RESTORE

RESTORE

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to find out if a medical technology called the Revi System active therapy (system is being implanted and activated) is better than non-active Revi system therapy (system is being implanted but not activated) for the treatment of urinary urge incontinence (UUI).

Who Can Participate?

Eligibility

Women ages 18+ who:
  • Has been diagnosed with UUI for at least 6 months
  • Do not have impaired kidney function
  • Have a body mass index (BMI) that is less than 50
For more information about the study, contact the study team at paige.green@duke.edu.

Age Range

18-110

Sex/Genders

Female (cisgender)
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join this study, you will receive the active REVI System therapy for the duration of the study. We will schedule you come to our clinic for check-ups and keep in touch with you after the device is activated to keep track of your symptoms. We will track your symptoms for 24 months. The REVI System is an implanted device. A small cut in the skin near the ankle is made so that it can be implanted along the tibial nerve. The devices works through a process called neuromodulation, which stimulates the nervous system in a way that can change the way nerves carry information to and from the brain. When you get the study device implanted, you will also get a random assignment (like a coin flip) to 1 of 2 groups:
  • One group will have their device begin the neuromodulation process 1 month after it is implanted.
  • The other group will have their device begin the neuromodulation process 4 months after it is implanted.

Locations

Other

Visit Timing

Weekdays

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

A PROSPECTIVE RANDOMIZED CONTROL TRIAL TO COMPARE THE EFFICACY OF THE REVI SYSTEM THERAPY ON VERSUS OFF IN RELIEVING URINARY URGE INCONTINENCE EPISODES

Principal Investigator

Cindy
Amundsen

Protocol Number

PRO00114306

Phase

III

Enrollment Status

Open to Enrollment